Psychedelic Medicine Task Force

Welcome Psychedelic Medicine Task Force members!

Please use this time to test your Zoom meeting controls located at the bottom of the screen:









Access **Mural** via the link sent to you in your meeting invitation. Only members have access to this shared workspace. Once on the site, minimize the screen for later use during the meeting.

Task Force staff

MDH staff

- **Dana Farley**, Alcohol & Drug Prevention Policy Director, Drug Overdose Prevention Unit Supervisor
- **Chrissie Deutsch**, Psychedelic Medicine Program Administrator
- **Dr. Caroline Johnson**, Psychedelic Medicine Scientific Researcher

Task Force chair

- Dr. Jessica Nielson

MAD staff

- Jessica Burke, Senior Management Consultant
- Nick Kor, Senior Management Consultant
- Stacy Sjogren, Senior Management Consultant

Welcome meeting observers

Thank you for your interest in the work of the

Psychedelic Medicine Task Force!

This meeting will not be recorded. **Minutes will be posted on the task force's website** along with other materials for this meeting:

https://www.health.state.mn.us/people/psychmed/index.html

health.psychedelicmemedicine@state.mn.us

Legislative charge

The Psychedelic Medicine Task Force was established to advise the legislature on the legal, medical, and policy issues associated with the legalization of psychedelic medicine in the state. For purposes of this work, “psychedelic medicine” means MDMA, psilocybin, and LSD.

Task force duties

as outlined in legislation (Subd. 5.)

Scientific Research

1. Survey existing studies in the scientific literature on the therapeutic **efficacy** of psychedelic medicine in the treatment of mental health conditions, including depression, anxiety, post-traumatic stress disorder, bipolar disorder, and **any other mental health conditions and medical conditions** for which a psychedelic medicine may provide an **effective** treatment option.
2. Compare the efficacy of psychedelic medicine in treating the conditions described [above] with the efficacy of treatments currently used for these conditions.

Duties

Develop a comprehensive plan that covers:

1. statutory changes necessary for the legalization of psychedelic medicine.

2. state and local regulation of psychedelic medicine

3. federal law, policy, and regulation of psychedelic medicine, with a focus on retaining state autonomy to act without conflicting with federal law, including methods to resolve conflicts.

    - Such as seeking an administrative exemption to the federal Controlled Substances Act under United States Code, title 21, section 822(d), and Code of Federal Regulations, title 21, part 1307.03; seeking a judicially created exemption to the federal Controlled Substances Act; petitioning the United States Attorney General to establish a research program under United States Code, title 21, section 872(e); using the Food and Drug Administration's expanded access program; and using authority under the federal Right to Try Act

4. Education of the public on recommendations made to the legislature and others about necessary and appropriate actions related to the legalization of psychedelic medicine in the state.

Work Cadence

Identify benefits and challenges of legalization Identify policy areas to focus on for work groups *barriers TBD as group work and research continue*		**Plan development + recommendations** *continual review through work group updates, SME presentations, and TF collaborative decision-making*					**Information synthesis, narrowing, and prioritization of report** *research and workgroup(s) continue if needed*		**Drafting of recommendations** *continue information synthesis, narrowing, and prioritization of report as draft takes shape*			**Submit Report Jan 1, 2025**
Dec 12/4/23	**Jan** 1/8/24	**Feb** 2/5/24	**March** 3/4/24	**April** 4/1/24	**May** 5/6/24	**June** 6/3/24	**July** 7/1/24	**Aug** 8/5/24	**Sept** 9/9/24	**Oct** 10/7/24	**Nov** 11/4/24	**Dec** 12/2/24	**Jan 1 TF ends**
	Determine initial subgroups **Draft initial legislative report due Feb 1**							**Begin outlining** Determine potential cost of implementation, needed investments, sustainable supports, etc.					Report includes comprehensive plan, scientific research, and any other additional materials members find necessary to share.

Today's agenda

- Approve January 8 meeting minutes
- Update on surveying of scientific literature
- Legal overview presentation
- **Break**
- Work group status reports
- Finalize charter
- Final report formatting preliminary discussion

Initial Survey of Scientific Literature

Dr. Caroline Johnson | Psychedelic Medicine Scientific Researcher

DEPARTMENT OF HEALTH

Overview of Section

- Overview of search results for Question 1
  - What are the health conditions that each drug shows efficacy and/or effectiveness in treating?
- Initially identified health conditions, PubMed
  - LSD
  - Psilocybin
  - MDMA
- Journal of Indigenous Research

Initial PubMed Results

	LSD	Psilocybin	MDMA	Total
Total number of results	211	169	247	627
Number of results discussing health conditions	45	61	31	138
Number of primary studies discussing health conditions	33	30	20	83

LSD

- Depression, anxiety:
  - With a life-threatening illness: 4 studies
  - Without a life-threatening illness: 1 study
  - Existential dread/general palliative care: 6 studies
- Substance Use Disorders:
  - Alcohol Use Disorder: 16 studies
  - Narcotic Use Disorder: 1 study
- Cluster Headache: 4 studies
- Pain: 1 study
- Schizophrenia: 2 studies

Psilocybin

- Depression, anxiety:
  - With a life-threatening illness: 4 studies
  - Without a life-threatening illness: 15 studies
  - Bipolar type 2: 1 study
  - Obsessive-compulsive disorder: 1 study
- Substance Use Disorders:
  - Alcohol Use Disorder: 3 studies
  - Tobacco Use Disorder: 3 studies
- Cluster Headache, Migraine: 3 studies
- Anorexia Nervosa: 1 study

MDMA

- Post-Traumatic Stress Disorder (PTSD): 14 studies
  - Treatment of symptoms within PTSD: 2 studies
- Anxiety Disorders:
  - Social anxiety in autistic adults: 2 studies
  - In response to a life-threatening illness: 1 study
- Tinnitus: 1 study

Journal of Indigenous Research

- Returned zero results using the agreed-upon search terms
- 6 Rs
  - Respect, Relationship, Representation, Relevancy, Responsibility, Reciprocity
- Expansion of search
- Workgroups focus: Cultural/Anthropological

Timeline

Month	Research Tasks
February	Narrative report of Question 1
February—March	Search & draft of Questions 2 (comparison) & 3 (risks), LSD
March—April/May	Search & draft of Questions 2 & 3, Psilocybin
May—June/July	Search & draft of Questions 2 & 3, MDMA
July—August	Additional search for any new publications between February—June
August—September	Drafting, editing, formatting, integrating literature review information
September—October	Any additional edits
November	Scientific review largely finalized
December	Any small final edits

Legal Overview

Dr. Mason Marks, MD, JD

Visiting Professor of Law, Harvard Law School; Florida Bar Health Law Section Professor, Florida State University; Visiting Fellow, Yale Law School Information Society Project

Work Groups: Updates

- **Upcoming meetings**
  - **Legal: Tomorrow (Feb. 6) @4pm – future meetings to typically be held first Thursday of each month.**
  - **Regulatory – Mon., Feb. 12 @4pm – Meetings held second Monday of each month.**
  - **Policy – Thur., Feb. 22 @4pm – Meetings as needed**
    - We have tentative monthly meeting times set aside but this work area will be less of a standalone work group. This is due to member overlap in work groups, reliance on initial legal and regulatory determinations, and legislative charge/process.

Reminder: Limited planning team capacity. This work and the comprehensive report will be determined by members. Any research will need to be identified by task force members and any experts members work with (e.g., today's speaker) unless otherwise provided by support staff.

Legal Work Group

- **State legal needs to address**
  - **Legislative charge:** Identify statutory changes necessary for the legalization of psychedelic medicine.
    - What statutes would need to **change** to legalize psychedelic medicine? What is relevant to **add**? (e.g., regulatory must haves)
    - **Member determination for March: Exemption vs. rescheduling** a drug under the state's CSA (consider state approach to medical cannabis and how other states are addressing statutory changes)
- **Federal legal needs to address**
  - **Legislative charge:** Address relevant methods the state should utilize or otherwise consider to retain state autonomy and resolve conflict with federal law.
    - **Methods to consider as outlined under legislation:** Administrative exemption to Federal Controlled Substances Act (CSA); Judicially created exemption to CSA; Petition U.S. AG to establish research program; FDA's expanded access program; Authority under federal Right to Try Act
    - **Member determination for March:** What approach do you think MN should take in addressing federal conflicting law?

Final report outline

1. Executive summary
   - Recommendations
2. Introduction
   - Task force charge and duties
   - Task force membership
3. Background
4. Path to task force recommendations
5. Task force recommendations
6. Public education plan
7. Appendices

Next steps and adjournment

- **Opportunity for member feedback:** please leave your feedback in Mural.
- **Questions between meetings:** contact Jess Burke (jessica.burke@state.mn.us)
- Next meeting: Monday, March 4, 2024, 9:30 am – 12:30 pm